Azithromycin is associated with increased survival in lung transplant recipients with bronchiolitis obliterans syndrome

Journal of Heart and Lung Transplantation

Volumn 29, Issue 5, 2010, Pages 531-537

  Jain, Raksha ^a   Hachem, Ramsey R ^a   Morrell, Matthew R ^a   Trulock, Elbert P ^a   Chakinala, Murali M ^a   Yusen, Roger D ^a   Huang, Howard J ^a   Mohanakumar, Thalachallour ^a   Patterson, G Alexander ^a   Walter, Michael J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

azithromycin; bronchiolitis; chronic rejection; lung transplant; macrolides; survival

Indexed keywords

AZITHROMYCIN;

ADULT; ARTICLE; BRONCHIOLITIS OBLITERANS; CONTROLLED STUDY; FEMALE; FORCED EXPIRATORY VOLUME; GRAFT RECIPIENT; HUMAN; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; RETROSPECTIVE STUDY; RISK FACTOR; RISK REDUCTION; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; BRONCHIOLITIS OBLITERANS; CAUSE OF DEATH; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; POSTOPERATIVE COMPLICATIONS; PROPORTIONAL HAZARDS MODELS; PSEUDOMONAS INFECTIONS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 77950518522     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2009.12.003     Document Type: Article

References (32)

1. Trulock E.P., Christie J.D., Edwards L.B., et al. Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult lung and heart-lung transplantation report-2007. J Heart Lung Transplant 26 (2007) 782-795
2. Christie J.D., Carby M., Bag R., et al. Registry of the International Society for Heart and Lung Transplantation: twenty-fifth official adult lung and heart/lung transplantation report-2008. J Heart Lung Transplant 27 (2008) 957-969
3. Williams T.J., and Verleden G.M. Azithromycin: a plea for multicenter randomized studies in lung transplantation. Am J Respir Crit Care Med 172 (2005) 657-659
4. Fujii T., Kadota J., Kawakami K., et al. Long term effect of erythromycin therapy in patients with chronic Pseudomonas aeruginosa infection. Thorax 50 (1995) 1246-1252
5. Kudoh S., Azuma A., Yamamoto M., et al. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit Care Med 157 (1998) 1829-1832
6. Jaffe A., Francis J., Rosenthal M., et al. Long-term azithromycin may improve lung function in children with cystic fibrosis. Lancet 351 (1998) 420
7. Gerhardt S.G., McDyer J.F., Girgis R.E., et al. Maintenance azithromycin therapy for bronchiolitis obliterans syndrome: results of a pilot study. Am J Respir Crit Care Med 168 (2003) 121-125
8. Verleden G.M., and Dupont L.J. Azithromycin therapy for patients with bronchiolitis obliterans syndrome after lung transplantation. Transplantation 77 (2004) 1465-1467
9. Verleden G.M., Vanaudenaerde B.M., Dupont L.J., et al. Azithromycin reduces airway neutrophilia and interleukin-8 in patients with bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 174 (2006) 566-570
10. Yates B., Murphy D.M., Forrest I.A., et al. Azithromycin reverses airflow obstruction in established bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 172 (2005) 772-775
11. Gottlieb J., Szangolies J., Koehnlein T., et al. Long-term azithromycin for bronchiolitis obliterans syndrome after lung transplantation. Transplantation 85 (2008) 36-41
12. Shitrit D., Bendayan D., Gidon S., et al. Long-term azithromycin use for treatment of bronchiolitis obliterans syndrome in lung transplant recipients. J Heart Lung Transplant 24 (2005) 1440-1443
13. Khalifah A.P., Hachem R.R., Chakinala M.M., et al. Respiratory viral infections are a distinct risk for bronchiolitis obliterans syndrome and death. Am J Respir Crit Care Med 170 (2004) 181-187
14. Khalifah A.P., Hachem R.R., Chakinala M.M., et al. Minimal acute rejection after lung transplantation: a risk for bronchiolitis obliterans syndrome. Am J Transplant 5 (2005) 2022-2030
15. Hachem R.R., Khalifah A.P., Chakinala M.M., et al. The significance of a single episode of minimal acute rejection after lung transplantation. Transplantation 80 (2005) 1406-1413
16. Mikols C.L., Yan L., Norris J.Y., et al. IL-12 p80 is an innate epithelial cell effector that mediates chronic allograft dysfunction. Am J Respir Crit Care Med 174 (2006) 461-470
17. Yousem S.A., Berry G.J., Cagle P.T., et al. Revision of the 1990 working formulation for the classification of pulmonary allograft rejection. J Heart Lung Transplant 15 (1996) 1-15
18. Estenne M., Maurer J.R., Boehler A., et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant 21 (2002) 297-310
19. Christie J.D., Carby M., Bag R., et al. Report of the ISHLT working group on primary lung graft dysfunction. Part II: Definition. A consensus statement of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 24 (2005) 1454-1459
20. Nathan S.D., Ross D.J., Belman M.J., et al. Bronchiolitis obliterans in single-lung transplant recipients. Chest 107 (1995) 967-972
21. Lama V.N., Murray S., Lonigro R.J., et al. Course of FEV(1) after onset of bronchiolitis obliterans syndrome in lung transplant recipients. Am J Respir Crit Care Med 175 (2007) 1192-1198
22. DiGiovine B., Lynch III J.P., Martinez III F.J., et al. Bronchoalveolar lavage neutrophilia is associated with obliterative bronchiolitis after lung transplantation: role of IL-8. J Immunol 157 (1996) 4194-4202
23. Zheng L., Walters E.H., Ward C., et al. Airway neutrophilia in stable and bronchiolitis obliterans syndrome patients following lung transplantation. Thorax 55 (2000) 53-59
24. Riise G.C., Andersson B.A., Kjellstrom C., et al. Persistent high BAL fluid granulocyte activation marker levels as early indicators of bronchiolitis obliterans after lung transplant. Eur Respir J 14 (1999) 1123-1130
25. Elssner A., Jaumann F., Dobmann S., et al. Elevated levels of interleukin-8 and transforming growth factor-beta in bronchoalveolar lavage fluid from patients with bronchiolitis obliterans syndrome: proinflammatory role of bronchial epithelial cells. Transplantation 70 (2000) 362-367
26. Yamada T., Fujieda S., Mori S., et al. Macrolide treatment decreased the size of nasal polyps and IL-8 levels in nasal lavage. Am J Rhinol 14 (2000) 143-148
27. Basyigit I., Yildiz F., Ozkara S.K., et al. The effect of clarithromycin on inflammatory markers in chronic obstructive pulmonary disease: preliminary data. Ann Pharmacother 38 (2004) 1400-1405
28. Tateda K., Ishii Y., Matsumoto T., et al. Direct evidence for antipseudomonal activity of macrolides: exposure-dependent bactericidal activity and inhibition of protein synthesis by erythromycin, clarithromycin, and azithromycin. Antimicrob Agents Chemother 40 (1996) 2271-2275
29. Page Jr. R.L., Ruscin J.M., Fish D., et al. Possible interaction between intravenous azithromycin and oral cyclosporine. Pharmacotherapy 21 (2001) 1436-1443
30. Palmer S.M., Miralles A.P., Howell D.N., et al. Gastroesophageal reflux as a reversible cause of allograft dysfunction after lung transplantation. Chest 118 (2000) 1214-1217
31. Cantu III E., Appel III J.Z., Hartwig M.G., et al., J. Maxwell Chamberlain Memorial Paper. Early fundoplication prevents chronic allograft dysfunction in patients with gastroesophageal reflux disease. Ann Thorac Surg 78 (2004) 1142-1151
32. Davis Jr. R.D., Lau C.L., Eubanks S., et al. Improved lung allograft function after fundoplication in patients with gastroesophageal reflux disease undergoing lung transplantation. J Thorac Cardiovasc Surg 125 (2003) 533-542